JP2022153413A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022153413A5 JP2022153413A5 JP2022108509A JP2022108509A JP2022153413A5 JP 2022153413 A5 JP2022153413 A5 JP 2022153413A5 JP 2022108509 A JP2022108509 A JP 2022108509A JP 2022108509 A JP2022108509 A JP 2022108509A JP 2022153413 A5 JP2022153413 A5 JP 2022153413A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- amino
- alkoxy
- hydroxy
- intron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 738
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 124
- 125000003282 alkyl amino group Chemical group 0.000 claims description 118
- 125000003545 alkoxy group Chemical group 0.000 claims description 106
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 102
- 239000002773 nucleotide Substances 0.000 claims description 81
- 125000003729 nucleotide group Chemical group 0.000 claims description 81
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 59
- 125000000623 heterocyclic group Chemical group 0.000 claims description 46
- 108700005078 Synthetic Genes Proteins 0.000 claims description 45
- 108020005067 RNA Splice Sites Proteins 0.000 claims description 43
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 40
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 40
- 125000003118 aryl group Chemical group 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 37
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 36
- 125000001424 substituent group Chemical group 0.000 claims description 36
- 108020004999 messenger RNA Proteins 0.000 claims description 33
- 229930024421 Adenine Natural products 0.000 claims description 29
- 229960000643 adenine Drugs 0.000 claims description 29
- GFFGJBXGBJISGV-UHFFFAOYSA-N adenyl group Chemical group N1=CN=C2N=CNC2=C1N GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 29
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 26
- 238000011144 upstream manufacturing Methods 0.000 claims description 25
- 125000003342 alkenyl group Chemical group 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 19
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 18
- 125000000304 alkynyl group Chemical group 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 229910052805 deuterium Inorganic materials 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 108700024394 Exon Proteins 0.000 claims description 17
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 14
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 12
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 108091092195 Intron Proteins 0.000 claims description 10
- 108091027974 Mature messenger RNA Proteins 0.000 claims description 10
- 125000004414 alkyl thio group Chemical group 0.000 claims description 10
- 125000001769 aryl amino group Chemical group 0.000 claims description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 6
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 6
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 6
- 125000005100 aryl amino carbonyl group Chemical group 0.000 claims description 6
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 6
- 125000001475 halogen functional group Chemical group 0.000 claims description 6
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims description 6
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 6
- 239000006166 lysate Substances 0.000 claims description 6
- 239000003607 modifier Substances 0.000 claims description 6
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 239000013592 cell lysate Substances 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 239000013598 vector Substances 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 10
- 238000004113 cell culture Methods 0.000 claims 5
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 4
- ZACWYYKZMLGOTG-UHFFFAOYSA-N 2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(1-ethylpiperidin-4-yl)-9-methylpyrido[1,2-a]pyrimidin-4-one Chemical compound C1CN(CC)CCC1C1=CN2C(=O)C=C(C3=NN4C=C(C)N=C(C)C4=C3)N=C2C(C)=C1 ZACWYYKZMLGOTG-UHFFFAOYSA-N 0.000 claims 4
- ZUYOOCCQYSTVKL-UHFFFAOYSA-N 2-(4,6-dimethylpyrazolo[1,5-a]pyrazin-2-yl)-7-(4-methylpiperazin-1-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound C1CN(C)CCN1C1=CN2C(=O)C=C(C3=NN4C=C(C)N=C(C)C4=C3)N=C2C=C1 ZUYOOCCQYSTVKL-UHFFFAOYSA-N 0.000 claims 4
- GYFRQCMDLBNZSF-UHFFFAOYSA-N 2-(4-ethyl-6-methylpyrazolo[1,5-a]pyrazin-2-yl)-9-methyl-7-(1-methylpiperidin-4-yl)pyrido[1,2-a]pyrimidin-4-one Chemical class C1=C2C(CC)=NC(C)=CN2N=C1C(N=C1C(C)=C2)=CC(=O)N1C=C2C1CCN(C)CC1 GYFRQCMDLBNZSF-UHFFFAOYSA-N 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 2
- 239000012458 free base Substances 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 238000010353 genetic engineering Methods 0.000 claims 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 2
- 239000013603 viral vector Substances 0.000 claims 2
- 241000710929 Alphavirus Species 0.000 claims 1
- 241000711404 Avian avulavirus 1 Species 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 108091034057 RNA (poly(A)) Proteins 0.000 claims 1
- 241000700618 Vaccinia virus Species 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000005030 transcription termination Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 229910018540 Si C Inorganic materials 0.000 description 8
- 229910010271 silicon carbide Inorganic materials 0.000 description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 6
- 241001024304 Mino Species 0.000 description 5
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Chemical group C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426619P | 2016-11-28 | 2016-11-28 | |
| US62/426,619 | 2016-11-28 | ||
| JP2019528527A JP2019535789A (ja) | 2016-11-28 | 2017-11-27 | Ｒｎａスプライシングを調節する方法 |
| PCT/US2017/063323 WO2018098446A1 (en) | 2016-11-28 | 2017-11-27 | Methods for modulating rna splicing |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528527A Division JP2019535789A (ja) | 2016-11-28 | 2017-11-27 | Ｒｎａスプライシングを調節する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022153413A JP2022153413A (ja) | 2022-10-12 |
| JP2022153413A5 true JP2022153413A5 (https=) | 2023-01-31 |
Family
ID=62195368
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528527A Pending JP2019535789A (ja) | 2016-11-28 | 2017-11-27 | Ｒｎａスプライシングを調節する方法 |
| JP2022108509A Pending JP2022153413A (ja) | 2016-11-28 | 2022-07-05 | Ｒｎａスプライシングを調節する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528527A Pending JP2019535789A (ja) | 2016-11-28 | 2017-11-27 | Ｒｎａスプライシングを調節する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11702646B2 (https=) |
| EP (1) | EP3544435A4 (https=) |
| JP (2) | JP2019535789A (https=) |
| CN (1) | CN110352007A (https=) |
| AU (1) | AU2017363369A1 (https=) |
| CA (1) | CA3043755A1 (https=) |
| EA (1) | EA201991309A1 (https=) |
| MX (1) | MX2019005588A (https=) |
| WO (1) | WO2018098446A1 (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4249472A3 (en) | 2015-05-30 | 2023-12-13 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| EA201991309A1 (ru) | 2016-11-28 | 2019-11-29 | Способы модуляции сплайсинга рнк | |
| KR20200017476A (ko) | 2017-06-14 | 2020-02-18 | 피티씨 테라퓨틱스, 인크. | Rna 스플라이싱의 변경 방법 |
| WO2019028440A1 (en) | 2017-08-04 | 2019-02-07 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICING |
| US20210355509A1 (en) * | 2018-08-07 | 2021-11-18 | The Children's Hospital Of Philadelphia | Alternative splicing regulation of gene expression and therapeutic methods |
| EP3864161A4 (en) * | 2018-10-09 | 2022-11-23 | The University of North Carolina at Chapel Hill | Regulated gene editing system |
| WO2020163248A1 (en) | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| CN114126613A (zh) | 2019-02-05 | 2022-03-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| EP3920915A4 (en) | 2019-02-05 | 2022-10-05 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICE |
| WO2020163544A1 (en) | 2019-02-06 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| CN113661162A (zh) | 2019-02-06 | 2021-11-16 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| EP4004213A1 (en) | 2019-07-25 | 2022-06-01 | Novartis AG | Regulatable expression systems |
| EP4017979A4 (en) * | 2019-08-19 | 2024-03-27 | Stoke Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MODULATING PROTEIN SPLICING AND EXPRESSION |
| CN115151540A (zh) | 2019-12-02 | 2022-10-04 | 风暴治疗有限公司 | 作为mettl3抑制剂的多杂环化合物 |
| CA3167756A1 (en) * | 2020-02-04 | 2021-08-12 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with son of sevenless 2 (sos2) inhibitors |
| CN115605596A (zh) * | 2020-02-12 | 2023-01-13 | 费城儿童医院（Us） | 用于基因表达的诱导型可变剪接调节的组合物和方法 |
| WO2021174167A1 (en) | 2020-02-28 | 2021-09-02 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| CA3169697A1 (en) | 2020-02-28 | 2021-09-02 | Dominic Reynolds | Thiophenyl derivatives useful for modulating nucleic acid splicing |
| JP7736700B2 (ja) | 2020-02-28 | 2025-09-09 | リミックス セラピューティクス インコーポレイテッド | 複素環アミド及びスプライシングを調節するためのその使用 |
| MX2022010634A (es) | 2020-02-28 | 2023-01-19 | Remix Therapeutics Inc | Derivados de piridazina para modular el empalme de acidos nucleicos. |
| JP2023520916A (ja) | 2020-04-08 | 2023-05-22 | リミックス セラピューティクス インコーポレイテッド | スプライシングを調整するための化合物及び方法 |
| KR20230005210A (ko) | 2020-04-08 | 2023-01-09 | 레믹스 테라퓨틱스 인크. | 스플라이싱을 조절하기 위한 화합물 및 방법 |
| BR112022023025A2 (pt) | 2020-05-13 | 2023-03-28 | Chdi Foundation Inc | Moduladores de htt para tratar doença de huntington |
| EP4175956A1 (en) | 2020-07-02 | 2023-05-10 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| EP4178963A1 (en) | 2020-07-02 | 2023-05-17 | Remix Therapeutics Inc. | 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| WO2022214520A1 (en) * | 2021-04-07 | 2022-10-13 | Janssen Sciences Ireland Unlimited Company | Antibacterial compounds |
| CN116087519B (zh) * | 2021-05-17 | 2025-03-14 | 郑州大学第一附属医院 | 一种用于高危人群贲门腺癌早期筛查的标志物及其应用 |
| CN113604566B (zh) * | 2021-07-13 | 2023-05-16 | 中山大学孙逸仙纪念医院 | lncRNA BCYRN1在膀胱癌预后、治疗中的应用 |
| WO2023034836A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2023034812A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20240400584A1 (en) | 2021-08-30 | 2024-12-05 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20240368163A1 (en) | 2021-08-30 | 2024-11-07 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| IL311132A (en) | 2021-08-30 | 2024-04-01 | Remix Therapeutics Inc | Splicing Modulation Compounds and Methods |
| CA3233973A1 (en) | 2021-10-13 | 2023-04-20 | Dominic Reynolds | Compounds and methods for modulating nucleic acid splicing |
| WO2023064879A1 (en) | 2021-10-13 | 2023-04-20 | Remix Therapeutics Inc. | Compounds and methods for modulating nucleic acid splicing |
| US12281116B2 (en) | 2021-11-17 | 2025-04-22 | Chdi Foundation, Inc. | HTT modulators for treating Huntington's disease |
| US20250326748A1 (en) | 2022-01-05 | 2025-10-23 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20250109140A1 (en) | 2022-01-05 | 2025-04-03 | Remix Theraputics Inc. | 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| WO2023133217A1 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| CN118647405A (zh) * | 2022-01-25 | 2024-09-13 | 上海魁特迪生物科技有限公司 | 改善认知障碍的方法 |
| WO2024036143A2 (en) * | 2022-08-09 | 2024-02-15 | Ptc Therapeutics, Inc. | Methods for modulating rna splicing |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3558618A (en) | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
| US4122274A (en) | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| JPS56150091A (en) | 1980-03-28 | 1981-11-20 | Janssen Pharmaceutica Nv | 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US5599816A (en) | 1990-05-02 | 1997-02-04 | Abbott Laboratories | Quinolizinone type compounds |
| EP0640083A1 (en) | 1992-05-13 | 1995-03-01 | E.I. Du Pont De Nemours And Company | Substituted pyrido 1,2-a]pyrimidinone derivatives as fungicides |
| KR19990022524A (ko) | 1995-06-06 | 1999-03-25 | 웨인스톡 스티븐 에프. | 퀴놀리지논형화합물 |
| US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
| AU5991699A (en) | 1998-09-21 | 2000-04-10 | Biochem Pharma Inc. | Quinolizinones as integrin inhibitors |
| WO2001030757A1 (en) | 1999-10-28 | 2001-05-03 | Microcide Pharmaceuticals, Inc. | Drug discharge pump inhibitors |
| CN1891693A (zh) | 2000-01-24 | 2007-01-10 | 基纳西亚股份有限公司 | 用于治疗的吗啉代基取代的化合物 |
| US7214515B2 (en) | 2001-01-05 | 2007-05-08 | The General Hospital Corporation | Viral delivery system for infectious transfer of large genomic DNA inserts |
| US20050009843A1 (en) | 2001-04-26 | 2005-01-13 | Kiyoshi Nakayama | Medicine for inhibiting drug elimination pump |
| ATE466581T1 (de) | 2001-12-07 | 2010-05-15 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
| GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| AU2003256755A1 (en) | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| CN1809563A (zh) | 2003-06-20 | 2006-07-26 | 希龙公司 | 吡啶并[1,2－a]嘧啶－4－酮化合物用作抗癌药 |
| ATE373659T1 (de) | 2004-05-04 | 2007-10-15 | Warner Lambert Co | Pyrrolylsubstituierte pyrido(2,3-d)pyrimidin-7- one und derivate davon als therapeutische mittel |
| AU2006206446A1 (en) | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| JP2008539698A (ja) * | 2005-04-29 | 2008-11-20 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 転写後レベルでの核酸発現調節のための方法および組成物 |
| US7563601B1 (en) | 2005-06-01 | 2009-07-21 | City Of Hope | Artificial riboswitch for controlling pre-mRNA splicing |
| WO2006138696A2 (en) | 2005-06-17 | 2006-12-28 | Genizon Biosciences, Inc. | Genemap of the human genes associated with longevity |
| WO2007110695A2 (en) | 2005-10-13 | 2007-10-04 | Bc Cancer Agency | Modular genomes for synthetic biology and metabolic engineering |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8110681B2 (en) | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| US8337941B2 (en) | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| JP5208962B2 (ja) | 2006-12-22 | 2013-06-12 | アベキサ・リミテッド | 二環式ピリミジノンおよびその使用 |
| WO2009151546A2 (en) | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| EP2138493A1 (en) | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
| PL2212324T3 (pl) | 2008-07-02 | 2014-11-28 | Avexa Ltd | Związki posiadające właściwości przeciwwirusowe |
| WO2010019243A1 (en) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc. | Methods for treating viral infections |
| CA2750379A1 (en) * | 2009-01-14 | 2010-07-22 | Gordon J. Lutz | Modulation of pre-mrna using splice modulating oligonucleotides as therapeutic agents in the treatment of disease |
| US20100303776A1 (en) | 2009-04-16 | 2010-12-02 | The University Of North Carolina At Chapel Hill | Methods and compositions for regulated expression of multiple nucleic acids |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| EP2501231B1 (en) | 2009-11-20 | 2016-12-21 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
| CN102812023A (zh) | 2010-01-13 | 2012-12-05 | 韩国巴斯德研究所 | 抗感染吡啶并(1,2-a)嘧啶类 |
| WO2012047487A1 (en) | 2010-09-27 | 2012-04-12 | Evolva Sa | 2-pyridone antimicrobial compositions |
| US9662314B2 (en) | 2011-10-21 | 2017-05-30 | Tufts Medical Center, Inc. | Compounds and methods for the treatment of muscular disease, and related screening methods |
| KR102057351B1 (ko) | 2011-12-30 | 2019-12-18 | 피티씨 테라퓨틱스, 인크. | 척수성 근위축증을 치료하기 위한 화합물 |
| PL2809322T3 (pl) | 2012-01-26 | 2019-11-29 | Ptc Therapeutics Inc | Związki do leczenia zaniku mięśni pochodzenia rdzeniowego |
| DK2812004T3 (en) * | 2012-02-10 | 2018-10-15 | Ptc Therapeutics Inc | COMPOUNDS FOR TREATMENT OF SPINAL MUSCLE DROPHY |
| CN104302181B (zh) | 2012-03-01 | 2017-09-15 | Ptc医疗公司 | 用于治疗脊髓性肌萎缩的化合物 |
| KR102109992B1 (ko) | 2012-03-23 | 2020-05-13 | 피티씨 테라퓨틱스, 인크. | 척수성 근위축증을 치료하기 위한 화합물 |
| US9212209B2 (en) | 2012-07-13 | 2015-12-15 | Indiana University Research And Technology Corporation | Screening methods for spinal muscular atrophy |
| US9040712B2 (en) | 2013-01-23 | 2015-05-26 | Novartis Ag | Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions |
| WO2015024876A2 (en) | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
| WO2015095446A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| WO2015095449A1 (en) | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount rna transcripts |
| EP3082820B1 (en) | 2013-12-19 | 2022-07-20 | PTC Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| SI3143025T1 (sl) | 2014-05-15 | 2020-01-31 | F. Hoffmann-La Roche Ag | Spojine za zdravljenje spinalne mišične atrofije |
| WO2016042015A1 (en) * | 2014-09-16 | 2016-03-24 | Centre National De La Recherche Scientifique (Cnrs) | Method for evaluating developmental competence of an oocyte |
| WO2016128343A1 (en) | 2015-02-09 | 2016-08-18 | F. Hoffmann-La Roche Ag | Compounds for the treatment of cancer |
| EP3298017B1 (en) | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Compounds for treating spinal muscular atrophy |
| EP4249472A3 (en) | 2015-05-30 | 2023-12-13 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| EA201991309A1 (ru) | 2016-11-28 | 2019-11-29 | Способы модуляции сплайсинга рнк | |
| KR20200017476A (ko) | 2017-06-14 | 2020-02-18 | 피티씨 테라퓨틱스, 인크. | Rna 스플라이싱의 변경 방법 |
| WO2019028440A1 (en) | 2017-08-04 | 2019-02-07 | Skyhawk Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODULATING SPLICING |
| KR20200057071A (ko) | 2017-09-25 | 2020-05-25 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱 조절제의 스크리닝 및 확인을 위한 방법 및 조성물 |
-
2017
- 2017-11-27 EA EA201991309A patent/EA201991309A1/ru unknown
- 2017-11-27 CN CN201780084649.8A patent/CN110352007A/zh active Pending
- 2017-11-27 AU AU2017363369A patent/AU2017363369A1/en not_active Abandoned
- 2017-11-27 MX MX2019005588A patent/MX2019005588A/es unknown
- 2017-11-27 WO PCT/US2017/063323 patent/WO2018098446A1/en not_active Ceased
- 2017-11-27 CA CA3043755A patent/CA3043755A1/en active Pending
- 2017-11-27 JP JP2019528527A patent/JP2019535789A/ja active Pending
- 2017-11-27 US US16/463,775 patent/US11702646B2/en active Active
- 2017-11-27 EP EP17873550.2A patent/EP3544435A4/en not_active Withdrawn
-
2022
- 2022-07-05 JP JP2022108509A patent/JP2022153413A/ja active Pending
-
2023
- 2023-05-12 US US18/316,871 patent/US20230272367A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022153413A5 (https=) | ||
| JP2019535789A5 (https=) | ||
| JP6906591B2 (ja) | 筋特異的核酸調節エレメント並びにその方法及び使用 | |
| JP2020523365A5 (https=) | ||
| Babij et al. | Characterization of a mammalian smooth muscle myosin heavy-chain gene: complete nucleotide and protein coding sequence and analysis of the 5'end of the gene. | |
| ES2643576T3 (es) | Dúplex oligonucleotídicos que comprenden nucleótidos de tipo ADN y de tipo ARN y usos de los mismos | |
| KR20200017476A (ko) | Rna 스플라이싱의 변경 방법 | |
| US20190192691A1 (en) | Regulated biocircuit systems | |
| JP5823969B2 (ja) | 心臓特異的核酸調節因子ならびにこの方法および使用 | |
| Dunn et al. | Common variant of human NEDD4L activates a cryptic splice site to form a frameshifted transcript | |
| Nicolaides et al. | Analysis of the 5′ Region ofPMS2Reveals Heterogeneous Transcripts and a Novel Overlapping Gene | |
| TW201923077A (zh) | 用於基因組編輯之多核苷酸、組合物及方法 | |
| MX2007009349A (es) | Recombinasas de serina de sitio especifico y metodos de uso. | |
| ES2623464T3 (es) | Nuevo factor de viabilidad neuronal y su uso para tratar la distrofia de conos | |
| JP2020515572A (ja) | 横隔膜特異的核酸調節エレメントならびにその方法および使用 | |
| Järving et al. | On the evolutionary origin of cyclooxygenase (COX) isozymes: characterization of marine invertebrate COX genes points to independent duplication events in vertebrate and invertebrate lineages | |
| CA2831342A1 (en) | Medicament for liver regeneration and for treatment of liver failure | |
| JP2022536951A (ja) | 環状ポリリボヌクレオチドを投与する方法 | |
| US5843757A (en) | Human JTV1 gene overlaps PMS2 gene | |
| AU2012317159B2 (en) | Two plasmid mammalian expression system | |
| Lu et al. | Characterization of small nontranslated polyadenylylated RNAs in vaccinia virus-infected cells. | |
| ES2256885T3 (es) | Nuevas quimiocinas del tipo cc. | |
| JP2013034401A (ja) | アストロサイトで遺伝子を発現させるためのベクター | |
| WO2016104906A1 (ko) | 형질전환동물 제작을 위한 형질주입 시스템 | |
| CN114423863A (zh) | 用于细胞遗传修饰的表达构建体 |